Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.
Tanguy Seiwert, MD
Advertisement
Articles by Tanguy Seiwert, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
3
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
4
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
5